Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
29.70
-0.74 (-2.43%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,378,567
Open
30.39
Bid (Size)
29.50 (1)
Ask (Size)
30.25 (1)
Prev. Close
30.44
Today's Range
29.53 - 31.06
52wk Range
28.97 - 42.29
Shares Outstanding
32,250,236
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Collegium to Participate in Upcoming Investor Conferences
November 12, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Record Third Quarter 2024 Financial Results
November 07, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Performance
YTD
-4.90%
-4.90%
1 Month
-0.87%
-0.87%
3 Month
-22.27%
-22.27%
6 Month
-6.22%
-6.22%
1 Year
-1.69%
-1.69%
More News
Read More
Collegium Appoints Vikram Karnani as Chief Executive Officer
November 07, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
A Preview Of Collegium Pharmaceutical's Earnings
November 06, 2024
Via
Benzinga
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical
September 05, 2024
Via
Benzinga
The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts
August 09, 2024
Via
Benzinga
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
October 24, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
September 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Collegium Completes Acquisition of Ironshore Therapeutics
September 04, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
September 03, 2024
Via
Investor's Business Daily
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
August 28, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Organon Stock Sees Relative Strength Rating Rise To 91
August 27, 2024
Via
Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
August 20, 2024
Via
Investor's Business Daily
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Collegium Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals.
August 06, 2024
Via
Chartmill
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
July 29, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
NASDAQ:COLL is an undervalued gem with solid fundamentals.
July 16, 2024
Via
Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
June 28, 2024
Via
Investor's Business Daily
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
Via
InvestorPlace
NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
June 24, 2024
Via
Chartmill
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
June 13, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.